Funding Rounds
Post IPO, $850M
Nektar (1990, San Carlos) – Novel therapeutics based on advanced polymer conjugate chemistry technology platform
Post IPO, $300M
Kite Pharma (2009, Los Angeles, $100.3M) – Develops cancer immunotherapy products using genetic engineering
Series E, $100M
Constellation Pharma (2008, Cambridge, $348.6M) – Discovers and develops drugs in the field of epigenetics.
Investors: Deerfield, Fidelity Investments, Hillhouse Capital Group, Orbimed, SIRONA CAPITAL, Venrock, The Column Group, Third Rock Ventures, SR One, Casdin Capital, Topspin Partners, University of California Office of the President
Series B, $70M
Crescendo (2009, Cambridge, $109M) – Humabodies and conjugates to treat psoriasis and prostate cancer.
Investors: anderapartners.com, Sofinnova Partners, IP Group, Takeda Ventures, Quan Capital, EMBL Ventures
Series B, $64M
Eidos Therapeutics (2016, Palo Alto, $64M) – small-molecule treatment for transthyretin (TTR) amyloidosis.
Investors: RA Capital Management, Janus Henderson Investors, Viking Global Investors, Aisling Capital, Perceptive Advisors, Amzak Capital Management, BridgeBio
Series B, $60M
Corvidia Therapeutics (2016, Waltham, $86M) – Cardiovascular therapies leveraging functional genomics.
Investors: Venrock, anderapartners.com, HBM Healthcare Investments, Apple Tree Partners, MedImmune, Sofinnova Ventures, Fresenius Medical Care
Series B, $56M
Revolution Medicines (2014, Redwood City, $126M) – Discovering and developing novel anti-cancer targeted small molecule drugs.
Investors: Nextech Invest, Casdin Capital, Schroder Adveq, The Column Group, Third Rock Ventures
Series C, $55M
Arvinas (2013, New Haven, $111.6M) – Small molecule drugs to target and degrade disease causing proteins
Investors: Nextech Invest, Deerfield, Hillhouse Capital Group, SIRONA CAPITAL, Canaan Partners, 5AM Ventures, RA Capital Management, Orbimed, New Leaf Venture Partners
Series C, $52M
Magenta Therapeutics (2016, Cambridge, $150.5M) – Stem cell-based therapies for autoimmune disease, genetics blood disorders and cancer
Investors: Casdin Capital, EcoR1 Capital, Eventide Funds, bethematchbiotherapies.com, Access Industries
Series C, $50M
Tessa Therapeutics (2011, Singapore, $130M) – T Cell-based therapies for virus-related cancers.
Investors: Temasek, EDBI, Heliconia Capital Management, heritascapital.com
Post IPO, $50M
Prothena (2012, Dublin) – Antibodies for the treatment of AL amyloidosis, Parkinson’s disease and psoriasis.
Venture Debt, $45M
Omeros (1994, Seattle, $66.9M) – Small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and CNS disorders
Investors: CRG
Post IPO, $44.5M
Inventiva Pharma (2011, Daix) – Small molecules for the treatment of NASH, Systemic sclerosis, Mucopolysaccharidoses (rare disease) and cancers.
Investors: BVF Partners, Novo Holdings, Sofinnova Ventures
Series B, $41.1M
Enterprise Therapeutics (2014, Brighton, $53.0M) – Therapies for treatment of respiratory diseases such as cystic fibrosis.
Investors: Versant Ventures, Novartis Venture Fund, Forbion Capital Partners, Epidarex Capital, IP Group
Post IPO, $38.7M
Tracon Pharma (2005, San Diego, $50.5M) – Antibody therapeutics for cancer and fibrotic diseases.
Investors: Puissance Capital Management, New Enterprise Associates
M&A
- Novartis bets big on gene therapy with $8.7 billion AveXis deal Reuters
- Advent is said to near deal to acquire Sanofi Generics unit Livemint
- Biotech M&A rolls on as Alexion snaps up Wilson for $855 million Reuters
- HCL Technologies Acquires Life Sciences and Consumer Services Provider C3i Solutions Business Wire
- Fresenius pulls out of Akorn takeover over data integrity Reuters
- Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc. Business Wire
- Avara Pharmaceutical Services Finalizes Acquisition of GSK Consumer Healthcare facility in South Carolina PR Newswire
- Mylan to buy MS drug marketing rights from Israel’s Mapi Pharma Reuters
- Corona Remedies acquires two brands from Abbott Indiatimes
- Inception Neuroscience Program Acquired by Roche Business Wire
IPO
- Unity Biotech Files IPO to Bring Anti-Aging Drugs into Clinical Trials Xconomy
- Flagship’s Evelo Biosciences pitches $100M IPO for a new platform of monoclonal microbials EndPoints News
- MorphoSys Resolves a Capital Increase to Implement the Offering of 8,300,000 American Depositary Shares (ADS) in the United States Life-Sciences-Germany
- Alzheon Launches Roadshow for Initial Public Offering Business Wire
- Abpro planning $69M NASDAQ listing BioCentury
- Mereo BioPharma’s Rationale for Halting IPO Draws Skepticism BioSpace
- Arcus Biosciences’ $138 Million Initial Public Offering Global Legal Chronicle
- Surface Oncology reaches public markets in $108m IPO Global Corporate Venturing
- Menlo’s IPO hangover begins with a failed PhII for an old Merck castoff EndPoints News
- Unity Biotech Announces Potential Pricing for IPO Wall
Funds Raising Funds
- AXIM Biotech Secures Additional Funding to Advance Cannabidnoid-Based Clinical Development Program for Multiple Indications EconoTimes
FDA Approval
- FDA refuses to review Alkermes’ depression treatment, seeks more trials Reuters
- FDA approves Ultragenyx’s drug for rare form of rickets Reuters
- GW cannabis-derived epilepsy drug gets positive FDA staff review Reuters
- Rigel Website Shows Erroneous Information that Tavalisse Has Been Approved by the FDA BioSpace
- Dr. Reddy’s Laboratories and its U.S. subsidiary Promius Pharma announce the filing of an NDA for its migraine candidate Business Wire
- Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years Business Wire
- Glenmark gets USFDA nod for skin ointment Livemint
- US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukemia Business Wire
Regulatory Change
- Futility forces Pfizer to stop phase 3 trial of Inlyta for recurrent renal cell carcinoma Pharmaceutical Business Review
New Product Announcement
- ‘Site-less’ trials in mind, Novartis launches an app for ophthalmology research EndPoints News
- Acerus Announces Launch of URIVARX® in Canada Business Wire
- Natco Pharma launches 1st generic version of Oral tablets for Multiple Sclerosis Business Standard
- Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir PharmaGlobeNewswire
- Look at our new launches, GSK urges, as its respiratory woes steal the limelightFiercePharma
- Alcon introduces pre-loaded delivery system for the CyPass® Micro-Stent to enhance surgical experience PR Newswire
- Innovus Pharma Announces the Launch of its Hemorrhoid Drug Xyralid® in CanadaBioSpace
New Geo Entry
- CollPlant Opens a New rhCollagen Production Facility PR Newswire
- Amarantus Relocates Headquarters to WeWork at 110 Wall St. in New York City ADVFN
- Roche to launch startup in India BioSpectrum India
- Scythian Poised to Enter Argentina Cannabis Market GlobeNewswire
Business Partnership
- Ionis may get up to $300 million in licensing deal with AstraZeneca Reuters
Company Announcement
- AstraZeneca’s Tagrisso shows sustained PFS in phase 3 lung cancer trial Pharmaceutical Business Review
Earnings Release
- Pampg Quarterly Results Surpass Estimates News Amed
Research Partnership
- Pfizer in deal with Allogene to develop cancer cell therapies Reuters
- Biogen boosts investment in neurology with $1 billion Ionis deal Reuters
- Loxo, Illumina to partner for diagnostic tool targeting cancer Reuters
- Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy Business Wire
- Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors Business Wire
Lawsuit
- Samsung Bioepis goes to courts to defeat AbbVie patents covering Humira theinvestor.co.kr
- Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) To Contact The Firm GlobeNewswire